Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Konstantinos Papamichail, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Biography
National and Kapodistrian University of Athens, School of Health Sciences, Medical School , Greece MD07/1999
National and Kapodistrian University of Athens, School of Health Sciences, Medical School, GreecePhD07/2007

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Papamichail K, Clarke WT, Casteele NV, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020 Mar 05. PMID: 32147594.
    Citations:    
  2. Papamichael K, Cheifetz AS, Irving PM. New role for azathioprine in case of switching anti-TNFs in IBD. Gut. 2020 Feb 19. PMID: 32075889.
    Citations:    
  3. Negoescu DM, Enns EA, Swanhorst B, Baumgartner B, Campbell JP, Osterman MT, Papamichael K, Cheifetz AS, Vaughn BP. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflamm Bowel Dis. 2020 01 01; 26(1):103-111. PMID: 31184366.
    Citations:    
  4. Fudman DI, Papamichael K, Roemi L, Rao V, Falchuk KR, Leffler DA, Feuerstein JD. Effect of Consent and Educational Adjuncts to Consent on Patient Perceptions About Colonoscopy. J Clin Gastroenterol. 2019 09; 53(8):e316-e321. PMID: 30001290.
    Citations:    Fields:    
  5. Papamichael K, Juncadella A, Wong D, Rakowsky S, Sattler LA, Campbell JP, Vaughn BP, Cheifetz AS. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2019 Aug 14; 13(8):976-981. PMID: 30689771.
    Citations:    Fields:    
  6. Papamichael K, Papaioannou G, Cheifetz MA, Cheifetz AS. Bone of Contention: Helicobacter pylori and Osteoporosis-Is There an Association? Dig Dis Sci. 2019 10; 64(10):2736-2739. PMID: 31407131.
    Citations:    
  7. Politis DS, Katsanos KH, Papamichael K, Saridi M, Albani E, Christodoulou DK. Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores? World J Gastrointest Endosc. 2019 Jun 16; 11(6):424-426. PMID: 31236195.
    Citations:    
  8. Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019 08; 15(8):837-848. PMID: 31180729.
    Citations:    
  9. Papamichael K, Cheifetz AS. Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD Therapy. Dig Dis Sci. 2019 06; 64(6):1397-1398. PMID: 30927210.
    Citations:    
  10. Lin SC, Goldowsky A, Papamichael K, Cheifetz AS. The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. Inflamm Bowel Dis. 2019 05 04; 25(6):998-1005. PMID: 30590558.
    Citations:    Fields:    
  11. Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol. 2019 Apr 09. PMID: 30973355.
    Citations:    
  12. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1655-1668.e3. PMID: 30928454.
    Citations:    
  13. Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019; 10:2040622319838443. PMID: 30937157.
    Citations:    
  14. Papamichael K, Delitheos B, Mourouzis I, Pantos C, Tiligada E. L-Thyroxine induces thermotolerance in yeast. Cell Stress Chaperones. 2019 03; 24(2):469-473. PMID: 30737613.
    Citations:    
  15. Politis DS, Papamichael K, Katsanos KH, Koulouridis I, Mavromati D, Tsianos EV, Christodoulou DK. Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation. Ann Gastroenterol. 2019 Mar-Apr; 32(2):168-173. PMID: 30837789.
    Citations:    
  16. Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. Inflamm Bowel Dis. 2018 09 15; 24(10):2266-2271. PMID: 29718327.
    Citations:    Fields:    
  17. Danford CJ, Trivedi HD, Papamichael K, Tapper EB, Bonder A. Osteoporosis in primary biliary cholangitis. World J Gastroenterol. 2018 Aug 21; 24(31):3513-3520. PMID: 30131657.
    Citations:    Fields:    Translation:Humans
  18. Juncadella A, Papamichael K, Vaughn BP, Cheifetz AS. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Dig Dis Sci. 2018 11; 63(11):3067-3073. PMID: 30006816.
    Citations:    Fields:    
  19. Papamichael K, Vajravelu RK, Vaughn BP, Osterman MT, Cheifetz AS. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2018 Jun 28; 12(7):804-810. PMID: 29590345.
    Citations: 1     Fields:    Translation:Humans
  20. Papamichael K, Cheifetz AS. Letter: infliximab concentrations during induction therapy-one size does not fit all. Aliment Pharmacol Ther. 2018 05; 47(9):1334-1335. PMID: 29644743.
    Citations:    Fields:    
  21. Papamichael K, Cheifetz AS, Osterman MT. Reply. Clin Gastroenterol Hepatol. 2018 04; 16(4):598-599. PMID: 29555231.
    Citations:    Fields:    
  22. Clarke WT, Amin SS, Papamichael K, Feuerstein JD, Cheifetz AS. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation. Clin Immunol. 2018 06; 191:59-62. PMID: 29601854.
    Citations:    Fields:    
  23. Katsanos KH, Papamichael K, Feuerstein JD, Christodoulou DK, Cheifetz AS. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clin Immunol. 2019 09; 206:9-14. PMID: 29545207.
    Citations:    Fields:    
  24. Katsanos KH, Papamichael K, Cheifetz AS, Christodoulou DK. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):465-466. PMID: 29462402.
    Citations:    Fields:    Translation:Humans
  25. Papamichael K, Osterman MT, Siegel CA, Melmed GY, Dubinsky MC, Colombel JF, Hanauer SB, Cheifetz AS. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202. PMID: 29432749.
    Citations:    Fields:    Translation:Humans
  26. Papamichael K, Cheifetz AS. Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease. Aliment Pharmacol Ther. 2018 02; 47(3):436-437. PMID: 29314123.
    Citations:    Fields:    
  27. Papamichael K, Vajravelu RK, Osterman MT, Cheifetz AS. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018 03; 63(3):761-767. PMID: 29340807.
    Citations:    Fields:    Translation:Humans
  28. Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018 Jan 05; 12(1):17-31. PMID: 28981623.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  29. Grossberg LB, Papamichael K, Feuerstein JD, Siegel CA, Ullman TA, Cheifetz AS. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 12 19; 24(1):191-197. PMID: 29272486.
    Citations:    Fields:    
  30. Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018 02; 47(4):478-484. PMID: 29210094.
    Citations:    Fields:    
  31. Papamichael K, Cheifetz AS. Response to Reinink. Am J Gastroenterol. 2017 12; 112(12):1893-1894. PMID: 29215625.
    Citations:    Fields:    
  32. Feuerstein JD, Papamichael K, Popejoy S, Nadelson A, Lewandowski JJ, Geissler K, Martinez-Vazquez M, Leffler DA, Ariyabuddhiphongs K, Thukral C, Cheifetz AS. Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private Practice. Dig Dis Sci. 2018 01; 63(1):36-45. PMID: 29147880.
    Citations:    Fields:    Translation:Humans
  33. Katsanos KH, Papamichael K, Christodoulou DK, Cheifetz AS. Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission? Dig Liver Dis. 2017 12; 49(12):1332-1333. PMID: 28964677.
    Citations:    Fields:    Translation:Humans
  34. Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. World J Gastroenterol. 2017 Sep 14; 23(34):6197-6200. PMID: 28974885.
    Citations:    Fields:    Translation:Humans
  35. Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017 09; 23(9):1510-1515. PMID: 28816757.
    Citations: 1     Fields:    Translation:Humans
  36. Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T, Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Har-Noy O, Bossuyt P, Mantzaris G, Barreiro de Acosta M, Chaparro M, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, Ferrante M, Sonnenberg E, Siegmund B, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vermeire S, Ben-Horin S, Roblin X. Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. Inflamm Bowel Dis. 2017 09; 23(9):1605-1613. PMID: 28590343.
    Citations: 2     Fields:    Translation:HumansCells
  37. Grossberg LB, Vodonos A, Papamichael K, Novack V, Sawhney M, Leffler DA. Predictors of post-colonoscopy emergency department use. Gastrointest Endosc. 2018 02; 87(2):517-525.e6. PMID: 28859952.
    Citations:    Fields:    Translation:Humans
  38. Detrez I, Van Stappen T, Martín Arranz MD, Papamichael K, Gils A. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease. Ther Drug Monit. 2017 08; 39(4):344-349. PMID: 28328760.
    Citations: 1     Fields:    Translation:HumansAnimals
  39. Papamichael K, Osterman MT, Cheifetz AS. Reply. Clin Gastroenterol Hepatol. 2017 10; 15(10):1638-1639. PMID: 28603051.
    Citations:    Fields:    
  40. Papamichael K, Cheifetz AS. Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough? Aliment Pharmacol Ther. 2017 05; 45(9):1265-1266. PMID: 28370052.
    Citations:    Fields:    Translation:Humans
  41. Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, Cheifetz AS. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1580-1588.e3. PMID: 28365486.
    Citations: 16     Fields:    Translation:Humans
  42. Papamichael K, Cheifetz AS. Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy. Am J Gastroenterol. 2017 May; 112(5):673-676. PMID: 28220781.
    Citations: 6     Fields:    Translation:Humans
  43. Wauters L, Billiet T, Papamichael K, Ballet V, Joniau S, Verschueren P, Silversmit G, Van Assche G, Vermeire S, Ferrante M. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. Eur J Gastroenterol Hepatol. 2017 Jan; 29(1):84-90. PMID: 27603297.
    Citations:    Fields:    Translation:Humans
  44. Van Stappen T, Bollen L, Vande Casteele N, Papamichael K, Van Assche G, Ferrante M, Vermeire S, Gils A. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. Clin Transl Gastroenterol. 2016 Dec 08; 7(12):e206. PMID: 27929524.
    Citations: 3     
  45. Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, Gils A, Ferrante M. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. J Crohns Colitis. 2017 Jan; 11(1):53-59. PMID: 27402915.
    Citations: 7     Fields:    Translation:Humans
  46. Kopylov U, Katsanos KH, van der Woude CJ, Karmiris K, Hernandez V, Odes S, Papamichael K, Koutroubakis IE, Bojic D, Kaimakliotis I, Fiorino G, Papageorgiou N, Pineda JR, Strongili K, Sanroman L, Mantzaris GJ, Jojic N, Paspatis G, Christodoulou DK, Ben-Horin S, Tsianos EV. European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. Eur J Gastroenterol Hepatol. 2016 Jul; 28(7):802-6. PMID: 26894634.
    Citations: 1     Fields:    Translation:Humans
  47. Miligkos M, Papamichael K, Vande Casteele N, Mantzaris GJ, Gils A, Levesque BG, Zintzaras E. Efficacy and Safety Profile of Anti-tumor Necrosis Factor-a Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons. Clin Ther. 2016 Jun; 38(6):1342-1358.e6. PMID: 27091732.
    Citations: 2     Fields:    Translation:Humans
  48. Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. J Crohns Colitis. 2016 Sep; 10(9):1015-23. PMID: 27022161.
    Citations: 4     Fields:    Translation:Humans
  49. Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016 Oct; 7(4):289-300. PMID: 28839870.
    Citations: 8     
  50. Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf. 2016; 15(4):493-501. PMID: 26799429.
    Citations: 4     Fields:    Translation:Humans
  51. Papamichael K, Cheifetz AS. Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis. 2016 May; 10(5):507-9. PMID: 26874348.
    Citations: 1     Fields:    Translation:Humans
  52. Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):543-9. PMID: 26681486.
    Citations: 19     Fields:    Translation:Humans
  53. Papamichael K, Karatzas P, Mantzaris GJ. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease. J Crohns Colitis. 2016 Mar; 10(3):371-2. PMID: 26546496.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  54. Mantzaris GJ, Papamichael K. Author's reply to Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: disease activity as an influencing factor. Scand J Gastroenterol. 2016 Mar; 51(3):382. PMID: 26425891.
    Citations:    Fields:    Translation:Humans
  55. Mantzaris GJ, Viazis N, Polymeros D, Papamichael K, Bamias G, Koutroubakis IE. Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol. 2015 Oct-Dec; 28(4):417-25. PMID: 26424173.
    Citations: 2     
  56. Papamichael K, Karatzas P, Theodoropoulos I, Kyriakos N, Archavlis E, Mantzaris GJ. Simethicone adjunct to polyethylene glycol improves small bowel capsule endoscopy imaging in non-Crohn's disease patients. Ann Gastroenterol. 2015 Oct-Dec; 28(4):464-8. PMID: 26423317.
    Citations: 1     
  57. Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015 Nov; 42(10):1158-69. PMID: 26365281.
    Citations: 8     Fields:    Translation:Humans
  58. Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F, Singh S, Ferrante M, Van Assche G, Vermeire S. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease. J Crohns Colitis. 2015 Dec; 9(12):1120-6. PMID: 26351386.
    Citations: 3     Fields:    Translation:Humans
  59. Potaris K, Kapetanakis E, Papamichail K, Midvighi E, Verveniotis A, Parissis F, Apostolou D, Tziortziotis V, Maimani S, Pouliara E, Vogiatzis G, Kakaris S, Konstantinou M. Major Lung Resections Using Manual Suturing Versus Staplers During Fiscal Crisis. Int Surg. 2015 Jul 27. PMID: 26215660.
    Citations:    Fields:    
  60. Mantzaris GJ, Tsironikos D, Tzanetakou X, Grispou E, Karatzas P, Kalogeropoulos I, Papamichael K. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy. Scand J Gastroenterol. 2015; 50(12):1451-5. PMID: 26139305.
    Citations:    Fields:    Translation:HumansPHPublic Health
  61. Ferrante M, Papamichael K, Duricova D, D'Haens G, Vermeire S, Archavlis E, Rutgeerts P, Bortlik M, Mantzaris G, Van Assche G. Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence. J Crohns Colitis. 2015 Aug; 9(8):617-24. PMID: 25926532.
    Citations: 4     Fields:    Translation:Humans
  62. Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor a therapy in inflammatory bowel disease. World J Gastroenterol. 2015 Apr 28; 21(16):4773-8. PMID: 25944990.
    Citations: 5     Fields:    Translation:Humans
  63. Papamichael K, Karatzas P, Mantzaris GJ. Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn's disease. J Crohns Colitis. 2015 Jul; 9(7):589-90. PMID: 25863276.
    Citations: 3     Fields:    Translation:Humans
  64. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. PMID: 25222660.
    Citations: 13     Fields:    Translation:Humans
  65. Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1103-10. PMID: 25478919.
    Citations: 11     Fields:    Translation:Humans
  66. Papamichael K, Konstantopoulos P, Mantzaris GJ. Helicobacter pylori infection and inflammatory bowel disease: is there a link? World J Gastroenterol. 2014 Jun 07; 20(21):6374-85. PMID: 24914359.
    Citations: 16     Fields:    Translation:HumansCells
  67. Kassi G, Papamichael K, Papaioannou G, Giagourta I, Thanou S, Triantaphyllopoulou M, Zapanti E, Papandroulaki F, Ktena V, Karga H. Cytokines and insulin resistance after zoledronic acid-induced acute phase response. Immunol Invest. 2014; 43(6):544-55. PMID: 24661204.
    Citations: 2     Fields:    Translation:Humans
  68. Makris M, Aggelides X, Chliva C, Katoulis A, Papamichael K, Tiligada E. High baseline blood histamine levels and lack of cross-reactivity in a patient with ranitidine-induced anaphylaxis. J Investig Allergol Clin Immunol. 2014; 24(5):361-3. PMID: 25345311.
    Citations:    Fields:    Translation:Humans
  69. Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, Kopylov U, Tsianos E, Mantzaris GJ, Ben-Horin S, Danese S, Fiorino G. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014 Feb; 46(2):135-9. PMID: 24246151.
    Citations: 11     Fields:    Translation:Humans
  70. Papamichael K, Karatzas P, Mantzaris GJ. Faecal calprotectin but not C-reactive protein (CRP) or Crohn's Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn's disease. J Crohns Colitis. 2013 Dec; 7(12):e700-1. PMID: 23953238.
    Citations: 5     Fields:    Translation:Humans
  71. Gazouli M, Anagnostopoulos AK, Papadopoulou A, Vaiopoulou A, Papamichael K, Mantzaris G, Theodoropoulos GE, Anagnou NP, Tsangaris GT. Serum protein profile of Crohn's disease treated with infliximab. J Crohns Colitis. 2013 Nov; 7(10):e461-70. PMID: 23562004.
    Citations: 9     Fields:    Translation:HumansCells
  72. Papamichael K, Delitheos B, Tiligada E. A subset of histamine receptor ligands improve thermotolerance of the yeast Saccharomyces cerevisiae. J Appl Microbiol. 2013 Feb; 114(2):492-501. PMID: 23121472.
    Citations:    Fields:    Translation:AnimalsCells
  73. Papamichael K, Mantzaris GJ. Reply to Dr. Yamamoto's letter. J Crohns Colitis. 2013 May; 7(4):e158. PMID: 23040450.
    Citations:    Fields:    Translation:Humans
  74. Papamichael K, Archavlis E, Lariou C, Tsigka A, Mantzaris GJ. Granular cell tumour in a patient with Crohn's disease treated with infliximab: coincidence or causal relationship? Eur J Gastroenterol Hepatol. 2012 Jul; 24(7):857-9. PMID: 22475791.
    Citations: 1     Fields:    Translation:Humans
  75. Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohns Colitis. 2012 Oct; 6(9):924-31. PMID: 22424843.
    Citations: 13     Fields:    Translation:HumansPHPublic Health
  76. Kyriakos N, Papamichael K, Archavlis E, Agalos G, Mantzaris GJ. Long term safety and efficacy of H1N1 vaccine in a single-center cohort of IBD patients treated with immunomodulators and/or anti-TNFa biologics. J Crohns Colitis. 2012 Mar; 6(2):264-5. PMID: 22325186.
    Citations:    Fields:    Translation:HumansCells
  77. Papamichael K, Gazouli M, Karakoidas C, Panayotou I, Roma-Giannikou E, Mantzaris GJ. Association of TNF and Fc?R???A gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients. Ann Gastroenterol. 2011; 24(1):35-40. PMID: 24714240.
    Citations: 7     
  78. Papaioannou G, Michelis FV, Papamichael K, Karga H, Tiligada E. Blood lymphocyte blastogenesis in patients with thyroid dysfunction: ex vivo response to mitogen activation and cyclosporin A. Inflamm Res. 2011 Mar; 60(3):265-70. PMID: 20972816.
    Citations:    Fields:    Translation:HumansCells
  79. Karga H, Giagourta I, Papaioannou G, Doumouchtsis K, Polymeris A, Thanou S, Papamichael K, Zerva C. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin. Metabolism. 2011 May; 60(5):604-8. PMID: 20667564.
    Citations: 2     Fields:    Translation:Humans
  80. Koutroubakis IE, Drygiannakis D, Tsirogianni A, Oustamanolakis P, Karmiris K, Papamichael K, Mantzaris GJ, Kouroumalis EA. Antiglycan antibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci. 2011 Mar; 56(3):845-52. PMID: 20632100.
    Citations: 3     Fields:    Translation:Humans
  81. Papamichael K, Tsirogianni A, Papasteriades C, Mantzaris GJ. Low prevalence of antibodies to cyclic citrullinated peptide in patients with inflammatory bowel disease regardless of the presence of arthritis. Eur J Gastroenterol Hepatol. 2010 Jun; 22(6):705-9. PMID: 19525851.
    Citations: 5     Fields:    Translation:Humans
  82. Triantafillidis JK, Mantzaris G, Karagiannis J, Papavasilliou E, Papatheodoridis G, Fouskas J, Malgarinos G, Gikas A, Papamichael K, Mathou N, Symboulakis E, Karamanolis D. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab. Rev Med Chir Soc Med Nat Iasi. 2010 Jan-Mar; 114(1):85-90. PMID: 20509281.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  83. Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A, Karakoidas C, Koilakou S, Raptis N, Smyrnidis A, Agalos G, Karamanolis DG. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. Eur J Gastroenterol Hepatol. 2009 Sep; 21(9):1042-8. PMID: 20139856.
    Citations: 3     Fields:    Translation:Humans
  84. Delitheos B, Papamichael K, Tiligada E. Histamine modulates the cellular stress response in yeast. Amino Acids. 2010 Apr; 38(4):1219-26. PMID: 19653065.
    Citations:    Fields:    Translation:AnimalsCells
  85. Karga H, Papaioannou G, Polymeris A, Papamichael K, Karpouza A, Samouilidou E, Papaioannou P. The effects of recombinant human TSH on bone turnover in patients after thyroidectomy. J Bone Miner Metab. 2010; 28(1):35-41. PMID: 19548061.
    Citations: 3     Fields:    Translation:Humans
  86. Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J Gastroenterol. 2009 Jun 14; 15(22):2701-7. PMID: 19522019.
    Citations: 24     Fields:    Translation:HumansCells
  87. Michelis FV, Petrogiannopoulos CL, Papamichael KX, Kostakos ND, Kiagia EZ, Deliousis A, Zacharof AK. Lymphomatous pericardial effusion positive for Mycobacterium tuberculosis by PCR analysis. Int J Infect Dis. 2008 Sep; 12(5):564-5. PMID: 18406651.
    Citations:    Fields:    Translation:Humans
  88. Petrogiannopoulos C, Papamichael K, Karachalios G, Karachaliou I, Kostakos N, Barbati K, Zacharof A. Autoimmune cholangitis presented as fever of unknown origin. Chemotherapy. 2006; 52(6):282-4. PMID: 17008778.
    Citations:    Fields:    Translation:Humans
  89. Tiligada E, Papamichael K, Vovou I, Delitheos A. Circumvention of camptothecin-induced resistance during the adaptive cellular stress response. Anticancer Res. 2006 Jan-Feb; 26(1A):421-5. PMID: 16475727.
    Citations:    Fields:    Translation:Animals
  90. Papamichael K, Vovou I, Miligkos V, Stavrinidis E, Delitheos A, Tiligada E. Effect of the Hsp90 modulators on the heat-shock response in eukaryotic cells. Folia Microbiol (Praha). 2006; 51(1):33-7. PMID: 16821709.
    Citations:    Fields:    Translation:Animals
  91. Miligkos V, Tiligada E, Papamichael K, Ypsilantis E, Delitheos A. Anticancer drugs as inducers of thermotolerance in yeast. Folia Microbiol (Praha). 2000; 45(4):339-42. PMID: 11347257.
    Citations: 2     Fields:    Translation:Animals
  92. Tiligada E, Miligkos V, Ypsilantis E, Papamichael K, Delitheos A. Molybdate induces thermotolerance in yeast. Lett Appl Microbiol. 1999 Aug; 29(2):77-80. PMID: 10499293.
    Citations: 3     Fields:    Translation:Animals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Papamichail's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (275)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.